A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.
Treprostinil is available in three different formulations and four different routes of administration: Remodulin®(treprostinil sodium, intravenous and subcutaneous administration), Tyvaso®(treprostinil sodium, inhaled administration), and Orenitram®(treprostinil diolamine, oral administration) for the treatment of pulmonary arterial hypertension (PAH). Pharmacokinetic studies have been performed in healthy volunteers and patients with PAH. The intent of this review is to outline pharmacokinetic considerations of the three treprostinil formulations and provide clinicians with a resource that may support clinical decisions in treating patients with PAH.
United Therapeutics Corporation, 55 T.W. Alexander Drive, PO Box 14186, Research Triangle Park, NC, 27709, USA.|Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Bethesda, MD, USA.
Parag
P
Kumar
United Therapeutics Corporation, 55 T.W. Alexander Drive, PO Box 14186, Research Triangle Park, NC, 27709, USA.
Emily
E
Thudium
United Therapeutics Corporation, 55 T.W. Alexander Drive, PO Box 14186, Research Triangle Park, NC, 27709, USA.
Kevin
K
Laliberte
United Therapeutics Corporation, 55 T.W. Alexander Drive, PO Box 14186, Research Triangle Park, NC, 27709, USA.
David
D
Zaccardelli
United Therapeutics Corporation, 55 T.W. Alexander Drive, PO Box 14186, Research Triangle Park, NC, 27709, USA. ANelsen@unither.com.
Andrew
A
Nelsen
D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D002940:Circadian Rhythm; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004347:Drug Interactions; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D020714:Maximum Tolerated Dose; D008657:Metabolic Clearance Rate
D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D011464:Epoprostenol; C427248:treprostinil